latanoprost and Pruritus

latanoprost has been researched along with Pruritus* in 2 studies

Trials

2 trial(s) available for latanoprost and Pruritus

Article	Year
A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma. Annals of ophthalmology (Skokie, Ill.), 2006,Summer, Volume: 38, Issue:2 We compared latanoprost monotherapy therapy with timolol/ dorzolamide in patients with primary open-angle glaucoma to evaluate the effects on intraocular pressure (IOP) and occurrence of adverse events. IOP and topical side effects were evaluated at the beginning, first, and third months. Mean IOP was decreased at the third month. The most common side effect was hyperemia (43.6%). We concluded that latanoprost reduces IOP better than fixed combination and its topical side effects are tolerable. Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Eye Color; Eyelashes; Female; Glaucoma, Open-Angle; Humans; Hyperemia; Intraocular Pressure; Latanoprost; Male; Middle Aged; Pain; Prostaglandins F, Synthetic; Pruritus; Sulfonamides; Thiophenes; Timolol	2006
The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2004, Volume: 20, Issue:4 We evaluated the efficacy and safety of latanoprost eye drops once-weekly, compared to once-daily for improving patient compliance. Twenty (20) patients (11 women and 9 men), 12 with ocular hypertension and 8 with early glaucoma, were studied after washout of the antiglaucoma treatment. One (1) group was treated with latanoprost once-daily (control). The other group was treated once-weekly (study group). Intraocular pressure (IOP) was measured at baseline and on the 2nd, 4th, 6th, and 9th day after the last drop in the study group, and for 3 months on the same schedule thereafter. The mean baseline IOP was 24.3 +/- 3.9 mmHg in the study group (range, 18-29) and 24.4 +/- 4.4 mmHg in the control group (range, 17-32). The average IOP at all time points of post-treatment was 17.7 +/- 1.5 mmHg (range, 14-23) and 16.9 +/- 2.30 mmHg (range, 13-21), respectively. Latanoprost significantly lowered IOP in both groups (study group, p = 0.005; controls, p = 0.0019). The difference between post-treatment IOP was insignificant in both groups at each time point. The study group had fewer minor side effects than the control group (1/10 versus 6/10, respectively). Latanoprost treatment once-weekly was as effective, and bore fewer minor side effects, as once-daily treatment after 3 months of follow-up. Topics: Adult; Aged; Analysis of Variance; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Patient Compliance; Prostaglandins F, Synthetic; Pruritus; Statistics, Nonparametric	2004

Article

Year

A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma.

Annals of ophthalmology (Skokie, Ill.), 2006,Summer, Volume: 38, Issue:2

We compared latanoprost monotherapy therapy with timolol/ dorzolamide in patients with primary open-angle glaucoma to evaluate the effects on intraocular pressure (IOP) and occurrence of adverse events. IOP and topical side effects were evaluated at the beginning, first, and third months. Mean IOP was decreased at the third month. The most common side effect was hyperemia (43.6%). We concluded that latanoprost reduces IOP better than fixed combination and its topical side effects are tolerable.

Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Eye Color; Eyelashes; Female; Glaucoma, Open-Angle; Humans; Hyperemia; Intraocular Pressure; Latanoprost; Male; Middle Aged; Pain; Prostaglandins F, Synthetic; Pruritus; Sulfonamides; Thiophenes; Timolol

2006

The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2004, Volume: 20, Issue:4

We evaluated the efficacy and safety of latanoprost eye drops once-weekly, compared to once-daily for improving patient compliance. Twenty (20) patients (11 women and 9 men), 12 with ocular hypertension and 8 with early glaucoma, were studied after washout of the antiglaucoma treatment. One (1) group was treated with latanoprost once-daily (control). The other group was treated once-weekly (study group). Intraocular pressure (IOP) was measured at baseline and on the 2nd, 4th, 6th, and 9th day after the last drop in the study group, and for 3 months on the same schedule thereafter. The mean baseline IOP was 24.3 +/- 3.9 mmHg in the study group (range, 18-29) and 24.4 +/- 4.4 mmHg in the control group (range, 17-32). The average IOP at all time points of post-treatment was 17.7 +/- 1.5 mmHg (range, 14-23) and 16.9 +/- 2.30 mmHg (range, 13-21), respectively. Latanoprost significantly lowered IOP in both groups (study group, p = 0.005; controls, p = 0.0019). The difference between post-treatment IOP was insignificant in both groups at each time point. The study group had fewer minor side effects than the control group (1/10 versus 6/10, respectively). Latanoprost treatment once-weekly was as effective, and bore fewer minor side effects, as once-daily treatment after 3 months of follow-up.

Topics: Adult; Aged; Analysis of Variance; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Patient Compliance; Prostaglandins F, Synthetic; Pruritus; Statistics, Nonparametric

2004